- Conditions
- Heart Failure, Pulmonary Disease, Chronic Obstructive, Interstitial Lung Disease
- Interventions
- Virtual Nurse and Social Worker Palliative Care Team, Enhanced Implementation Support, Standard Implementation Support
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 9,581
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Cancer
- Interventions
- Nivolumab, BMS-986205, Cetuximab, Cisplatin, Carboplatin, Fluorouracil
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Interventions
- atorvastatin, Tacrolimus, methotrexate
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Heart Failure, Coronary Artery Disease
- Interventions
- Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 5,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 115
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 112 more
- Conditions
- Postoperative Urinary Tract Infection
- Interventions
- Tamsulosin, Control Group
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Johns Creek, Georgia
- Conditions
- Osteosarcoma, Leukemia, Lymphoma
- Interventions
- glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin
- Drug
- Lead sponsor
- BTG International Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 20 more
- Conditions
- Gram-Negative Bacterial Infections
- Interventions
- Cefiderocol, Standard of Care
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- Up to 3 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • Durham, North Carolina
- Conditions
- Chronic Lung Disease, Pulmonary Hypertension
- Interventions
- Observational Study
- Diagnostic Test
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 100 participants
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- BRAFV600 Mutation, Stage IV Melanoma
- Interventions
- Radiation therapy, Vemurafenib
- Radiation · Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Bloodstream Infection
- Interventions
- GARNET device
- Device
- Lead sponsor
- Boa Biomedical, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 3 more
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Batiraxcept, Cabozantinib (Cabo), Nivolumab
- Drug
- Lead sponsor
- Aravive, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 13 more
- Conditions
- Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix
- Interventions
- Telaglenastat, Radiation treatment, Cisplatin
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Succinic Semialdehyde Dehydrogenase Deficiency
- Interventions
- Transcranial magnetic stimulation (TMS), Magnetic resonance imaging (MRI), Electroencephalogram (EEG), Bio-specimen Collection
- Device · Procedure
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Exercise Recovery
- Interventions
- HBOT
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- ECP Methoxsalen, Standard of Care
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 11
- States / cities
- Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more
- Conditions
- Soft Tissue Infections
- Interventions
- Standard care, beta-lactam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Melbourne, Florida + 4 more
- Conditions
- Stroke, Parkinson's Disease, Muscle Weakness
- Interventions
- Canine Animal-Assisted Therapy, Standard of Care Physical Therapy
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
- Interventions
- Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Neoplasms
- Interventions
- IMC-CS4
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Atlanta, Georgia + 3 more
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab, Standard of Care (SOC), Imsidolimab 750 mg IV/200 mg SC
- Drug · Other
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more
- Conditions
- Chronic Subdural Hematoma, Subdural Hematoma
- Interventions
- Embolization of the Middle Meningeal Artery, Standard of care including possible surgical evacuation of subdural hematoma
- Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Ketosis Prone Diabetes
- Interventions
- Continuous Glucose Monitoring, Insulin
- Device · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients
- Interventions
- Phrenic Nerve Stimulation
- Device
- Lead sponsor
- Lungpacer Medical Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- La Jolla, California • Shreveport, Louisiana • Winston-Salem, North Carolina + 3 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary
- Interventions
- Standard of Care + atorvastatin, Standard of Care (SOC)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado